Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor of Australian Small-Cap Investigator, a stock tipping newsletter that hunts down promising small-cap stocks by dissecting the latest events affecting the world.

To find out more about the publications Ryan works on and how you can subscribe, please click on the corresponding link here:

15/01/2021

Afterpay Is the Barometer for Bold Investing — Appetite for Risk

Yesterday, Afterpay Ltd (ASX:APT) added $3 billion to its market cap. Sure, they certainly have a captivating growth narrative. However, they also have a monstrous valuation relative to current sales...

Ryan Clarkson-Ledward

14/01/2021

Orthocell Share Price Up 25% on FDA Approval (ASX:OCC)

Drug development is a long and tedious process, often taking years to reach commercialisation. Small-cap biotech company Orthocell Ltd [ASX:OCC] knows this all too well, having spent years bringing their tissue repair...

Ryan Clarkson-Ledward

14/01/2021

Galan Lithium Grabs an 80% Stake in New Project, Shares Rise 10.5%

Galan confirmed this morning that it has acquired an 80% stake in the Greenbushes South project. Securing the deal via an agreement with their new partner Lithium Australia NL [ASX:LIT].

Ryan Clarkson-Ledward

14/01/2021

General Motors Unveils Electric Future — The Potential Lithium Boom

GM (the renowned carmaker) has made a huge splash at CES. Sharing their tech-centric vision for the future of the automotive industry. It’s pretty damn clear that GM is going all in on the electric vehicle trend...

Ryan Clarkson-Ledward

13/01/2021

Nanollose Share Price Soars 56% Thanks to Patent Application (ASX:NC6)

When it comes to small and microcap stocks, you can find some truly unique ventures. Take Nanollose Ltd [ASX:NC6] for instance. A company that classifies itself as a biomaterials maker...

Ryan Clarkson-Ledward

12/01/2021

Acrux Share Price Explodes Higher on FDA Approval (ASX:ACR)

When it comes to biotech stocks, the ultimate goal is always to get a drug to market. Acrux today shared the good news that their testosterone topic solution has been approved by the US Food & Drug Administration (FDA)...

Ryan Clarkson-Ledward

11/01/2021

Why the Liontown Resources Share Price is Volatile (ASX:LTR)

After surging at the market open today, the Liontown Resources Ltd [ASX:LTR] share price is down 1.1% at time of writing. Suffering a mixed day of trade in the wake of some speculative news...

Ryan Clarkson-Ledward

07/01/2021

Imugene Share Price Climbs 5% as Cancer Trial Closer to Commencing

Imugene Ltd [ASX:IMU] certainly finished 2020 with a bang. With a 5% lift in the IMU share price this morning, the stock is making waves once more. Today, it has since eased back from those record highs, but it is still faring well...

Ryan Clarkson-Ledward

07/01/2021

COVID-19 Could End ‘Made in China’ as We Know It

There is an exodus in China. It dawned on producers that relying only on China is risky. Then the coronavirus (COVID-19) struck. An event that could be the nail in the coffin of China’s manufacturing supremacy...

Ryan Clarkson-Ledward

06/01/2021

AD1 Share Price Moves Higher as Its ‘Art of Mentoring’ Platform Takes Off

Back in October, AD1 acquired a small business known as ‘Art of Mentoring’ (AoM). A unique venture that provided mentoring services to select professionals and corporations. All of which were branded as ‘best-in-class' services...